On robust runway for sustainable growth

Company
05 Jan 2024
5 Min read 
  • MEDANTA has delivered strong financial performance, with 3x earnings growth and a 35% EBITDA CAGR over the past four years.
  •  The company has turned net cash in FY23 from a net debt position in FY19.
  •  MEDANTA plans to expand its bed capacity to over 3,500 beds in the next two to three years, with a focus on adding beds in Noida, Indore, and South Delhi.
  •  The company expects a 6% CAGR in ARPOB and a 28% earnings CAGR over FY23-26.
  •  MEDANTA is valued at 26x 12-month forward EV/EBITDA, with a target price of INR1,170.
  •  The stock is rated as a "Buy" with a positive outlook for future growth.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority